Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.95 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4819900 | 1.00 | ALDH1A1 (0.95) | ALDH1A1KDM4ETDP1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL4821241 | 1.00 | ALDH1A1 (0.95) | ALDH1A1KDM4ETDP1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL2548 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4ETDP1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL5086756 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4ETDP1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL4556431 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4ETDP1CHRNB2CHRNA4 | |
| Iodide SCHEMBL238934 | 0.97 | ALDH1A1 (0.90) | ALDH1A1KDM4ETDP1CHRNB2CHRNA4 | |
| Iodide SCHEMBL16857350 | 0.97 | ALDH1A1 (0.90) | ALDH1A1KDM4ETDP1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL1250694 | 0.95 | KDM4E (0.85) | ALDH1A1KDM4ETDP1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL10608057 | 0.95 | ALDH1A1 (0.95) | ALDH1A1KDM4ETDP1CHRNB2CHRNA4 | |
| Iodide SCHEMBL16857345 | 0.95 | ALDH1A1 (0.85) | ALDH1A1KDM4ETDP1CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111757875-B | Dihydrobenzofuran and indene analogs as myocardial segment inhibitors | 赛特凯恩蒂克公司 | 2024-01-09 | — | — | CN | disclosed |
| US-8093406-B2 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2012-01-10 | — | — | US | disclosed |
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-7008940-B1 | Dihydrobenzofuran derivatives, process for the preparing thereof and agents | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-07 | — | — | US | disclosed |
| EP-1213290-B1 | DIHYDROBENZOFURAN DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND AGENTS | TAKEDA PHARMACEUTICAL (JP) | 2005-04-20 | — | — | EP | disclosed |
| US-6750349-B2 | SUPERIOR GASTROKINETIC PROPERTIES | JANSSEN PHARMACEUTICS, N.V. (BE) | 2004-06-15 | — | — | US | disclosed |
| EP-1000028-B1 | GASTROKINETIC MONOCYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2003-11-26 | — | — | EP | disclosed |
| US-20030078427-A1 | Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2003-04-24 | — | — | US | disclosed |
| US-6452013-B1 | FOR TREATING CONDITIONS WHICH ARE RELATED TO IMPAIRMENT OF GASTRIC EMPTYING | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-09-17 | — | — | US | disclosed |
| EP-1213290-A1 | DIHYDROBENZOFURAN DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND AGENTS | Takeda Chemical Industries, Ltd. (JP) | 2002-06-12 | — | — | EP | disclosed |
| EP-1000028-A1 | GASTROKINETIC MONOCYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002494-A1 | GASTROKINETIC MONOCYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078427-A1 | Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | HRH2, ALK, CBR1 | CHRM2 135/4885CHRM1 110/4885ALDH1A1 2457/4885 |
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | BACE2, BACE1, APP | CHRM2 4462/4885CHRM1 4773/4885ALDH1A1 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.